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Background: It is generally believed that patients with Hürthle cell thyroid carcinoma (HCTC) have a poor
prognosis. Furthermore, distant metastases represent the most frequent cause of thyroid cancer-related death
of patients with HCTC. The aim of this study was to report the treatment and outcomes of patients with
distant metastases.
Methods: Altogether 108 patients were treated for HCTC from 1972 to 2011 in our tertiary center and 32
patients (19 females, 13 males; median age 64.5 years) had either initially proven metastatic disease (N = 12)
or distant progression of HCTC after initial treatment (N = 20). Patients with metastases were followed for 1–226
(median 77) months. Data were collected on the patients’ gender and age, extent of their disease, morphologic
characteristics, therapy, outcome, and survival rate. Statistical correlation between possible prognostic factors and
cause-specific survival from time of detection of metastases was analyzed by univariate analysis and log-rank test.
Results: The most common were lung metastases, followed by bone, mediastinum, kidney, and liver in 24, 8, 2, 1,
and 1 case, respectively. Total thyroidectomy, lobectomy, subtotal thyroidectomy and neck dissection were performed
in 19, 10, 3, and 7 patients, respectively. Radioiodine (RAI) ablation of thyroid remnant was performed in 30 patients,
while 20 of them had RAI therapy (median 4 times). RAI uptake in metastases was present in 16 patients and ranged
from 0.05 % to 12 %. Chemotherapy was used in 13 patients and external beam radiotherapy in 19 patients.
Locoregional control of disease was achieved in 19/21 (90 %) cases who succumbed due to HCTC. Estimated 10-year
disease-specific survival for all patients was 60 %. 10-year disease-specific survival for patients with pulmonary
metastases and other sites metastases was 60 % and 62 %, respectively. 10-year disease-specific survival for
patients with single organ and multiple organ metastases was 52 %, and 100 %, respectively. Estimated median
disease-specific survival after the diagnosis of metastatic disease for all patients was 77 months. The median
disease-specific survival after the diagnosis of metastatic disease for patients with pulmonary metastases and
other sites metastases was 72 and 138 months, respectively.
Conclusions: Ten-year disease-specific survival for all patients with metastatic Hürthle cell thyroid carcinoma,
patients with pulmonary metastases and bone metastases was 60 %, 60 % and 68 %, respectively.
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Hürthle cell thyroid carcinoma (HCTC) is regarded to
be an oxyphilic variant of follicular thyroid cancer (FTC)
according to the World Health Organization classifica-
tion [1]. However, genomic studies revealed that HCTC
is a unique thyroid malignancy distinct from papillary
and follicular thyroid cancer [2]. HCTC is a rare type of
thyroid carcinoma [3] which comprises about 3 % of all
thyroid malignancies [4].
Only about 400 patients with HCTC were reported
from 1935 to 2004 [3]. There are several reports of
single-institution studies of patients with HCTC [5–23],
but only two recently published single-institution series
included more than 100 patients [22, 23]. Older studies re-
ported poor survival of patients with HCTC [5, 6, 8–10].
But in population-based studies from the United States,
Nagar et al. [24] and Bhattacharyya [2] reported that the
survival of patients with HCTC has improved dramatically
over time and that survival rates of HCTC and FTC are
currently the same. Unfortunately, the treatment of pa-
tients was not reported and causes of prolonged survival
were not explained.
In 2003, we reported that the uptake of radioiodine
(RAI) was confirmed in 11 of 16 patients with metastatic
HCTC [15]. The purpose of the present study was to
report the uptake of RAI in a larger number of patients
with metastatic HCTC. Another of this study’s aims was
to describe the treatment and outcome of 32 patients
with metastatic HCTC with a long follow-up period.
Methods
Altogether 108 patients were treated for HCTC at
our tertiary center from 1972 to 2011, and 32 patients (19
females, 13 males; median age 64.5 years) had either an
initially proven metastatic disease (N = 12; 9 females, 3
males; median age 66.5 years) or distant progression of
HCTC after initial treatment (N = 20; 10 females, 10
males; median age 64 years).
The Medical Ethics Committee of the Republic
Slovenia and The Protocol Review Board and Ethics
Committee of the Institute of Oncology approved the
study, which was conducted in accordance with the
ethical standards laid down in an appropriate version
of the 1964 Declaration of Helsinki. The need for
consent was waived by the Institutional Review Board
and Ethics Committee of the Institute of Oncology
Ljubljana. For retrospective studies a written consent is
deemed unnecessary according to national regulations.
As already reported in one of our previous studies
[23], all histological slides of our patients with HCTC
were examined by the pathologist (B.G.) experienced in
thyroid pathomorphology. HCTC was diagnosed on the
histological criteria defined by LiVolsi and Rosai [25, 26].
An oncocyte was characterized by the presence ofacidophilic, granular cytoplasm and hyperchromatic or
vesicular nuclei with large nucleolus. Only lesions demon-
strating more than 75 % of follicular cells with oncocytic
characteristics were included in the study group. All
patients with Hürthle cell neoplasms with cells containing
typical nuclear features of papillary carcinoma were
excluded from our present study and were the subject of
one of our previous studies [27]. The diagnosis of malig-
nancy for present study was based on histologic evidence
of transcapsular and/or vascular invasion, extrathyroidal
local tissue invasion by the primary tumor [25, 26], or
presence of nodal or distant metastasis.
A chart review was performed, and data on patients’
age, gender, disease history, extent of disease, histomor-
phological characteristics, mode of therapy, outcome, and
survival were collected. Clinical characteristics, treatment
of patients and their outcome are presented in Table 1,
Table 2 and Table 3.
The tumor stage, presence of regional and/or distant
metastases, as well as residual tumor after surgery were
assessed by the TNM clinical classification according to
the UICC criteria from 2009 [28]. The initial diagnostic
work-up in all patients with HCTC included ultrasound
(US) of the neck region, determination of the serum
thyroglobulin (Tg) concentration and chest X-ray. The
criteria for disease-free survival were Tg levels of less
than 1 ng/mL, negative whole-body RAI scans, and the
exclusion of cervical lymph node metastases by US.
Additional diagnostic work-up (X-ray, US, computed
tomography, magnetic resonance imaging, bone scintig-
raphy, scintigraphy with MIBI and/or PET-CT) was con-
ducted whenever the medical history, physical examination,
laboratory findings, and/or radioiodine (RAI) uptake indi-
cated recurrence and/or distant metastases.
All patients with HCTC had a follow-up exam at our
Institute at least once per year, while for all patients with
distant metastases follow-ups were conducted at least
twice per year. This consisted of obtaining medical
history, a physical examination, and determining serum
Tg concentration. Imaging was also conducted whenever
Tg concentration increased or clinical symptoms sug-
gested that the disease had progressed.
Treatment
During 30 year period, surgical treatment of primary
tumor, locoregional recurrences, and distant metastases
was not uniform; neither was the proportion of patients
treated by RAI ablation of thyroid remnant tissue, exter-
nal beam radiotherapy (EBRT), chemotherapy and RAI
therapy [23]. Surgery is the mainstay of the treatment of
HCTC. Among surgically treated patients, 84 % had pri-
mary surgery at the Institute of Oncology and 16 % else-
where, while all other specific therapies (surgery, RAI,
EBRT and/or chemotherapy) as well as follow-up were
Table 1 Patients’ and tumor characteristics and univariate statistical analysis of disease-specific survival
Factor Subgroup Initially metastatic (N = 12) Distant progression (N = 20) p-value
Gender Female 9 10 0.16
Male 3 10
Age at presentation (years) 64 or less 6 5 0.15
65 or more 6 15
Tumor diameter (cm) 0-4 3 4 0.74
4.01 and more 9 16
pT tumor stage pT0 or pT2 2 3 0.96
pT3 6 11
pT4 4 6
N stage N0 10 16 0.48
N1 (N1a + N1b) 2 4
M stage M0 12 0 -
M1 0 20
Thyroid surgical procedure Total or near-total thyroidectomy 6 13 0.40
Lobectomy or less 6 7
Neck dissection No 9 18 0.26
Yes 3 2
Residual tumor after surgery R0 – without residual tumor 3 12 0.066
R1 – microscopic residual tumor 8 5
R2– macroscopic residual tumor 1 3
Radioiodine ablation after surgery No 1 1 0.71
Yes 11 19
Therapy with radioiodine No 5 8 0.93
Yes 7 12
External beam irradiation - neck No 6 14 0.40
Yes 6 6
External beam irradiation – any site No 2 11 0.03
Yes 10 9
Chemotherapy No 4 16 0.008
Yes 8 4
Outcome Alive without disease 0 0 -
Alive with disease 2 9
Dead of disease 9 11
Dead of other causes 0 0
Lost to follow-up 1 0
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After surgery, all patients received therapy with L-
thyroxin for thyrotropin (TSH) suppression.
The data on the type of surgery for primary tumors
and treatment of distant metastasis are listed in Table 3.
Total or near-total thyroidectomy is considered a proper
surgical procedure for HCTC. Generally, after an inad-
equate surgical procedure a completion thyroidectomy is
performed. However, in our study group this was per-
formed in only one of 13 patients with inadequatesurgery. It was not performed if the patient had an injury
of recurrent nerve (N = 2), or if the patient was very old
or with severe comorbidities (N = 2), if the patient re-
fused another surgical procedure (N = 2), and preferred
treatment with RAI (N = 6).
Initial treatment in nine patients with a locally ad-
vanced tumor was neoadjuvant chemotherapy, while one
patient received concomitant EBRT with a tumor dose
of 36 Gy. Tumor size decreased in all of these patients,
and in 2 of 9 patients the largest tumor diameter




























1 85–89 85–89 7,5 3 0 1 L 7414 77 0 77 DDM
2 75–79 75–79 5 4b 0 1 L 4450 53 0 53 DOC
3 70–74 70–74 8 3 0 1 L 265 141 0 141 DDM
4 70–74 70–74 6 4a 0 1 B 183 13 0 13 DDM
5 65–69 65–69 8,5 3 0 1 L 16650 185 0 185 Alive
6 65–69 65–69 8 3 0 1 BL 4010 148 0 148 DDM
7 60–64 60–64 8 0 0 1 B No data 153 0 153 DDM
8 60–64 60–64 4,5 3 1b 1 L 62600 131 0 131 DDM
9 60–64 60–64 2 2 0 1 B 69 1 0 1 LFU
10 60–64 60–64 6,5 3 0 1 L 1300 72 0 72 DDM
11 55–59 55–59 5 4b 1b 1 L 190 201 0 201 DDM
12 45–49 45–49 9 4b 0 1 L 5800 52 0 52 DDM
13 85–89 85–89 12 3 0 0 Mediastinum 277 52 38 14 DDM
14 75–79 75–79 3 2 0 0 B 47 126 34 92 Alive
15 75–79 85–89 8 3 0 0 L 696 144 84 60 DDM
16 70–74 70–74 2 4a 1a 0 Kidney 1432 318 180 138 DDM
17 70–74 75–79 8 3 0 0 L 1300 63 36 2 DDLTP
18 70–74 80–84 6,8 3 0 0 L 1000 132 96 36 Alive
19 70–74 70–74 5,5 4a 0 0 L No data 26 3 23 DDM
20 65–69 65–69 3,6 3 0 0 L 0.1 46 43 3 Alive
21 65–69 70–74 7 4a 0 0 L No data 63 53 10 DDM
22 65–69 65–69 9 3 0 0 BL 1100 145 52 93 DDM
23 60–64 65–69 18 4b 1b 0 L 416 100 20 53 DDM
24 60–64 70–74 3 2 0 0 L, liver 501 121 84 36 DDM
25 60–64 65–69 4,5 3 0 0 L 30773 97 49 48 Alive
26 60–64 70–74 7 3 0 0 L 196 138 113 27 Alive
27 60–64 60–64 6,5 3 1a 0 B 763 43 16 27 Alive
28 60–64 60–64 8 4a 0 0 Mediastinum 1800 145 44 101 DDLTP
29 50–54 55–59 13 4b 0 0 L 800 75 26 42 DDM
30 50–54 75–79 6 3 0 0 L 163 337 31 65 DDM
31 50–54 50–54 3 2 1b 0 L Tg-antibodies 33 9 24 Alive
32 35–39 40–44 4 3 0 0 BL 108 286 60 226 Alive
Legend: B bone, L lungs, DDM dead of distant metastases, DOC dead of other causes, LFU lost to follow-up, DDLTP dead of distant and locoregional
tumor progression
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apy consisted of long infusion of low dose vinblastine
(2 mg in 12-h) in four patients and of vinblastine and
doxorubicin (20 mg in 2-h infusion) in two patients.
Neoadjuvant chemotherapy consisted of vinblastine,
doxorubicin and mitoxantrone in one patient, while in
two patients more than three cytostatic drugs were used
(vinblastine, doxorubicin, docetaxel and cisplatin in one
patient; vinblastine, cisplatin, doxorubicin, bleomycin,
cyclophosphamide, mitoxantrone in another one).Metastases in regional lymph nodes were treated sur-
gically by functional radical neck dissection in five as
part of primary treatment. Surgical therapy of meta-
static disease and/or locoregional recurrence was con-
ducted on nine patients (Table 3). It included neck
dissection, resection of lung metastasis, resection of
bone metastasis, resection of brain metastasis, resection
of liver metastasis, nephrectomy, laminectomy, hip re-
placement, superficial parotidectomy, tracheal shaving,
and tracheostomy.





















EBRT - neck and
mediastinum
(Dose in Gy)
EBRT of metastases Surgery for metastases
or recurrence
1 TT R0 No - 0 - No No No No No No
2 LO R1 Yes No 1 129 No No No Yes (50) No No
3 LO R1 Yes Yes 7 1066 No No No Yes (50) No No
4 LO R2 Yes No 1 94 Yes Yes Yes (36) Yes (36 + 15) Ribs, thorax No
5 TT R1 Yes Yes 4 500 Yes Yes No Yes (56) Lumbal vertebra, left
hip and left pelvis
No
6 LO R1 Yes Yes 8 1201 Yes Yes No No Thoracic vertebra -
rwice
No
7 PT R0 Yes No 2 250 No Yes No No Frontal part of skull,
left orbita
Resection of right clavicle
8 TT + RND R1 Yes No 1 100 Yes Yes No No Lungs twice No
9 TT R0 Yes No 1 94 No No No No No No
10 TT + RND R1 Yes Yes 8 1355 Yes Yes No Yes (50) No No
11 LO + RND R1 Yes Yes 8 1156 Yes Yes No Yes (45) Left hip twice, thorax,
right hip, brain, right
clavicle
No




13 TT R1 No - 0 - No No No No No No
14 TT R0 Yes Yes 5 779 No No No No No No
15 TT R0 Yes No 1 92 No No No No No Left hip replacemnt
16 LO R0 Yes Yes 6 1090 No No No No No Right nephrectomy
17 TT R0 Yes No 1 106 No No No No No No
18 TT R0 Yes No 1 261 No No No No No No
19 LO R0 Yes Yes 2 350 No No No No No No
20 TT R2 Yes No 1 100 No No No Yes (50) No Tracheal shaving of
recurrence
21 PT R2 Yes Yes 2 230 No No No No No No
22 TT R0 Yes Yes 2 300 No No No No Base of skull, lungs,
right neck
No
23 TT + RND R1 Yes No 1 100 Yes Yes No Yes (49) Clavicle No











Table 3 Treatment of patients (Continued)
25 TT R0 Yes No 2 244 No No No No No No
26 TT R0 Yes Yes 3 382 No No No No No No
27 TT + RND R1 Yes No 1 95 No Yes No Yes (50) Sternum, clavicle,
right tibia
No
28 LO R1 Yes Yes 11 1523 No Yes No Yes (50) No No
29 LO R2 Yes No 2 263 Yes Yes No Yes (51) Mediastinum, lungs Tracheostomy, mRND
30 LO R0 Yes Yes 2 230 No No No No Mediastinum, lungs Resection of lung metastasis
and twice brain matastasis
31 TT R0 Yes Yes 3 393 No No No No No Parotidectomy, mRND
32 TT R0 Yes No 1 95 No Yes No No Pelvis, left elbow,
lumbar vertebra
6 x lung metastasis, 5 x bone
metastasis, mediastinal lymph
nodes, liver metastasis, axillary
lymphadenectomy
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tissue in 30 (94 %) patients. All 13 patients with non-
adequate surgery had the ablation of thyroid remnant
tissue. The ablation dose was 3.4–4.8 GBq (92–129 mCi)
of RAI. RAI was used also for treating of distant metas-
tases and inoperable locoregional recurrences with em-
piric dose of 3.7–7.4 GBq (100–200 mCi). Patients with
distant metastases underwent total thyroidectomy prior
to treatment with RAI in order to increase the uptake of
iodine in metastases and to speed up the treatment
whenever possible. Before 2002, serum concentration of
TSH of >30 mU/L was achieved by a 4–6-week with-
drawal of L-thyroxin suppression therapy. Since 2002,
recombinant human TSH (rhTSH)-aided RAI therapy
[29] has been used in altogether eight patients who were
elderly with concomitant diseases, had a history of
severe hypothyroid or compressive symptoms and/or
evidence of tumor progression during thyroid hormone
withdrawal.
Altogether 13 patients were treated with chemother-
apy. Kinase inhibitors were not used in patients included
in the present report.
EBRT was done in a total of 19 patients, of whom
twelve received EBRT to the neck and superior mediasti-
num (3 after R2 resection and 9 after R1 resection).
Survival
Cause-specific survival was defined as the period from
primary treatment (surgery, chemotherapy or EBRT) to
death or the last follow-up.
Disease-free survival was defined as the period from
primary treatment (surgery, chemotherapy or EBRT) to
the radiologic or morphologic diagnosis of recurrence or
the last follow-up. The median duration of follow-up
was 8.3 years (range 0.1–28.1 years).
Statistical analysis
The Student t-test or the Mann–Whitney U-test was
used according to data distribution. The association be-
tween categorical variables was tested by the chi-square
test or Fisher’s exact test, as appropriate. All compari-
sons were two-sided and a p-value <0.05 was considered
statistically significant. The statistical correlation be-
tween possible prognostic factors and cause-specific
survival was analyzed by chi-square test and log rank
analysis. The survival curves were calculated according
to the Kaplan-Meier method. A multivariate statistical
analysis was not performed because of the small number
of patients. The statistical package PASW 18 (SPSS Inc.,
Chicago, IL, USA) was used for the analysis.
Results
The median age of patients with initially proven meta-
static disease (N = 12) and distant progression of HCTCafter initial treatment (N = 20) was 66.5 and 64 years,
respectively. The median age of both groups of patients
was not statistically different. A female-to-male ratio in
initially proven metastatic disease and distant progres-
sion after initial treatment was 3:1 and 1:1, respectively.
Gender distribution in both groups of patients was not
statistically different (p = 0.27).
The tumor diameter ranged from 2 to 18 cm (median
6.65 cm, mean 6.75 cm). Median tumor size in initially
metastatic disease and distant progression was 7 cm and
6.65 cm, respectively (p = 0.75). Extrathyroid tumor
growth was present in patients with and without initially
proven metastatic disease and 75 % and 40 %; respect-
ively (p = 0.27).
Single organ and multiple organ metastases at the time
of diagnosis of dissemination were diagnosed in 28 and
4 cases, respectively. The most common were lung me-
tastases, followed by bone, mediastinum, kidney, and
liver in 24, 8, 2, 1, and 1 case, respectively. Lung metas-
tases were present in patients with initially proven
metastatic disease and in patients with metastases after a
disease-free interval in 75 % (p = 1.0). Bone metastases
were present in patients with initially proven metastatic
disease and in patients with metastases after a disease-
free interval in 33 % and 20 %; respectively (p = 0.43).
Median Tg concentration at the diagnosis of metasta-
ses was 1050 ng/mL (range 47–62600 ng/mL).
Treatment
The data on the type of treatment of patients are sum-
marized in Table 1. All patients had surgical treatment
on their primary tumor. Total (or-near total) thyroidec-
tomy, lobectomy, subtotal thyroidectomy, and neck
dissection were performed in 19, 10, 3, and 7 patients,
respectively. RAI ablation of thyroid remnant was per-
formed in 30 patients, while RAI therapy was performed
in 20 of them. They received from 1 to 10 RAI therapies
(median 4) and cumulative RAI dose ranged from 6.21
to 41.16 GBq (230 to 1523 mCi) with a median cumula-
tive dose of 24–96 GBq (922 mCi). RAI uptake in metas-
tases was present in 16 patients and ranged from 0.05 %
to 12 % (median 0.5 %). In 9 of patients the uptake of
RAI was 0.5 % or larger. Chemotherapy and EBRT was
used in 13 and 18 patients, respectively.
The treatment of metastases was heterogeneous. Two
patients had surgery because of lung metastases. In the
first one a lung metastasis was excised because it was
solitary and occurred after a long disease-free interval.
The other patient had six surgical procedures because of
small multiple metastases which were resected at other
hospital because the patient preference and persistence.
The same patient had also numerous surgical procedures
of bone metastases. On the other hand, majority of bone
metastases in our patients lesions were efficiently treated
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necessitated surgical approach: a right hip replacement
because of fracture of femur and two surgical procedures
of the right ulna. Two patients had liver metastases: one
of them was treated with RAI eight times and there was
an uptake in liver metastases. The other patient had pul-
monary and liver metastases and RAI uptake was ob-
served in liver three times. Because of progression of
liver metastases and T3-hypethyreosis she was treated
also with chemotherapy (vinblastine and doxorubicin,
vinblastine and cisplatin) with only partial response.Disease-free survival and disease-specific survival
Following initial treatment, distant metastases were
proven in 20 patients after follow-up of 3 to 180 months
(median 44 month). Distant dissemination was diag-
nosed as only distant, both locoregional and distant, and
after surgical treatment of locoregonal recurrence in 11,
3, and 6 cases, respectively.
Nine patients are alive with a median follow-up of 33–
286 months. One patient was lost from follow-up. One
patient died of causes unrelated to primary disease,
while 21 patients died of thyroid carcinoma. Of the lat-
ter, 19 patients died of distant metastases, while two pa-
tients died of distant and locoregional progression of the
disease. Locoregional control of the disease was achieved
in 19/21 (90 %) patients who succumbed due to HCTC.
Table 4 shows details about median length of
disease-specific survival from the diagnosis of meta-
static disease, 5-year disease-specific survival and 10-
year disease-specific survival for all patients, those
with pulmonary, bone, single organ, multiple organ
metastases, initially metastatic, and metastatic after
disease-free interval.Table 4 Median estimated disease-specific survival, 5-year disease-sp
treatment and from the time of diagnosis of metastatic disease










All patients 145 81 60
Pulmonary metastases all patients 141 81 60
≤3 pulmonary metastases 100 67 44
>3 pulmonary metastases 141 77 55
Without pulmonary metastases 153 74 62
Bone metastases 148 70 68
Single organ metastases 131 77 52
Multiple organ metastases 145 100 10
Initially metastatic 141 76 52
Metastatic after disease-free
interval
145 81 60Patients treated with neoadjuvant chemotherapy had a
more advanced stage of disease than those who were not
treated by neoadjuvant chemotherapy (Table 2 and
Table 3). Estimated median disease-specific survival from
the beginning of treatment in patients with and without
neoadjuvant chemotherapy was 100 and 141 months
(log-rank p = 0.256), respectively. 5-year disease-specific
survival for patients with and without neoadjuvant
chemotherapy was 78 % and 90 %, respectively. Median
disease-specific survival from the diagnosis of meta-
static disease in patients with and without neoadjuvant
chemotherapy was 93 and 72 months, respectively (log-
rank p = 0.89).
Median disease-specific survival from the initial treat-
ment in patients with and without total thyroidectomy
was 145 months in both groups of patients. Median
disease-specific survival from the time of diagnosis of
distant metastases in patients with and without total thy-
roidectomy was 93 months and 65 months (p = 0.32),
respectively.
Median disease-specific survival from the initial treat-
ment of patients with and without RAI therapy was
145 months and 100 months, respectively. Median
disease-specific survival from the diagnosis of distant
metastases in patients with and without RAI therapy
was 93 months and 77 months, respectively. Patients
treated only with surgery and RAI without EBRT and/or
chemotherapy had median disease-specific survival
49 months from the initial therapy and 27 months from
the diagnosis of distant dissemination.
Discussion
HCTC is a rare disease, so there are only limited data about
treatment of patients with metastatic and/or locally ad-
vanced HCTC [3, 6, 7, 9, 11, 14–17, 20, 23, 29, 30] becauseecific survival and 10-year disease-specific survival from inital




















0 93 70 38
141 76 52
65 44 19
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ited number of patients. To our knowledge this study rep-
resents the largest group of patients with distant metastases
of HCTC and long follow-up in all the literature. Large pri-
mary tumors in our patients probably accounted for the
high frequency of metastatic disease in our population [23].
Since the data were gathered over 39 years, many of the
early cases were prior to the current epidemic of diagnosis
of small and limited tumors. But a limitation of our
study is that treatment was not uniform. Another limi-
tation of our study is that only one of 13 patients with
inadequate surgery underwent completion surgery, in-
cluding six patients who “preferred treatment with
RAI”.
Total thyroidectomy and RAI ablation of thyroid
remnant tissue have an impact on earlier detection of re-
currence and disease-free survival and possibly also on
cause-specific survival of patients with HCTC [23]. Pa-
tients with HCTC from different centers were treated with
various approaches. Total or near-total thyroidectomy was
conducted on patients reported by Kushchayeva et al. [1],
Har-El at al. [7], Chindris et al. [22], Petric et al. [23],
Khafif et al. [11], Mills et al. [20], Lopez-Penabad et al.
[16], and Stojadinovic et al. [14] in 90 %, 82 %, 81 %, 71 %,
64 %, 52 %, 47 %, and 30 % of cases, respectively. Add-
itionally, RAI ablation of thyroid remnant tissue was
conducted in those reported by Chindris et al. [22], Petric
et al. [23], Kushchayeva et al. [1], Mills et al. [20], Har-El
at al. [7], and Khafif et al. [11] in 87 %, 80 %, 64 %, 44 %,
18 %, and 9 %, respectively. EBRT to the neck region was
conducted in 28 %, 23 %, 21 %, 18 %, and 2 % of patients
reported by Lopez-Penabad et al. [16], Mills et al. [20],
Petric et al. [23], Kushchayeva et al. [1], and Chindris et al.
[22], respectively. The 10-year disease-specific survival
was 88 % [23] and only 49 % in a study reported by Petric
et al. [23] and Kushcayeva et al. [1], respectively. However,
it should be stressed that the survival rates represent the
result of both selection bias, i.e. more advanced disease in
larger centers, and the effectiveness of different treatment
modalities used in patients.
Our patients with metastatic HCTC had suppressed
TSH with L-thyroxin. Other treatment options for meta-
static HCTC are RAI, EBRT, surgery, chemotherapy,
and/or targeted therapy. There is a paradigm that metas-
tases of HCTC do not accumulate RAI. However, in
1994 Caplan et al. [9] reported normalization of elevated
Tg concentration in two cases of HCTC after treatment
with RAI [9]. Furthermore, in 2003, our group reported
the uptake of RAI (range 0.1–12 %) in 11 of 16 (69 %)
patients with distant metastases of HCTC from our ter-
tiary comprehensive cancer center [15]. The updated
data is presented in the current publication. RAI uptake
was present in metastases in 16 of 30 patients (53 %)
who had distant metastases. Uptake of RAI was 0.5 % orhigher in 9 of 30 patients (30 %). Similarly, Lopez-
Penabad et al. reported that 38 % of the patients with
known metastases of HCTC showed RAI uptake in the
period between 1944 and 1995 at the MD Anderson
Cancer Center [16]. However, former data from Mayo
Clinic are in disagreement with results from MD Ander-
son Cancer Center and our institute [22]. At Mayo, RAI
scintigraphy (either TSH-stimulated or in hypothyroid
state) was performed in 40 patients with metastases and
RAI uptake was seen in only 9 cases (22.5 %) [22]. A
possible reason for discrepant results may be the wide-
spread use of CT and PET-CT with iodine radio-
contrast media in the diagnostic work-up of patients
with suspected dissemination of HCTC in the States.
RhTSH-aided RAI may be effective in RAI avid meta-
static HCTC [29]. Numerous RAI-avid lesions were
detected after rhTSH aided RAI therapy in five of six of
our patients with HCTC [29]. Furthermore, 2 of 6
patients had partial response and one of them was long
lasting [29]. Our view is therefore that RAI therapy may
be effective treatment option in patients with HCTC
which should not be neglected in patients with RAI avid
metastases. Treatment with RAI has low toxicity and
price in comparison to the treatment with tyrosine kin-
ase inhibitors. We believe that they may be treatment
of choice when metastases are non-RAI avid. But stud-
ies should be performed to assess the role of tyrosine
kinase inhibitors in Hurthle cell carcinoma that is not
radio-iodine avid.
Also EBRT may be an effective treatment option in
metastatic HCTC. In 1986, Har-El et al. reported that
after incomplete resection and EBRT of inoperable neck
mass a patient survived 14 years [7]. Foote et al. from
the Mayo Clinic stated that HCTC is a radiosensitive
tumor [17]. Our data support their observation that
postoperative EBRT prevents the recurrence of advanced
resected tumors [17]. EBRT was conducted in a total of
19 patients, of whom twelve received EBRT to the neck
and superior mediastinum and long-lasting locoregional
control of disease was achieved in all three patients
after macroscopic residual tumor resection. Further-
more, our experience confirms observation from Mayo
Clinic that EBRT provide palliative relief from symp-
tomatic metastases [17]. The effect of EBRT of bone
metastases in our patients lasted from 13 to 165 months
(median 93 months).
Surgical procedure is another useful treatment option
for distant metastasis in selected cases. In our patients,
surgical therapy of metastatic disease and/or local recur-
rence included functional neck dissection, resection of
lung, bone, brain and liver metastasis, nephrectomy,
laminectomy, hip replacement, superficial parotidect-
omy, tracheal shaving, and tracheostomy. Khafif et al. re-
ported that one patient who had a resection of a lung
Besic et al. BMC Cancer  (2016) 16:162 Page 10 of 11metastasis was alive and free of disease 18 years after his
initial surgery [11].
Our previously published data showed that chemother-
apy may be effective in primary HCTC [30]. Chemother-
apy in neoadjuvant setting decreased size of primary
HCTC in 43 % of cases [30]. Lopez-Penabad et al. re-
ported that systemic chemotherapy was administered to
27 % of patients, mainly those with unresectable or pro-
gressive metastatic disease [16]. Thirteen percent of
patients received chemotherapy initially as a radiosensitiz-
ing agent, and the remaining 87 % of patients received a
full course of treatment [16]. The agents that were used
most commonly were doxorubicin alone in 43 % of
patients, doxorubicin plus cisplatin in 38 % of patients,
cisplatin alone in 10 % of patients, and an unspecified
agent in the reviewed records of 9 % of patients [16].
There is a bias about performing a total thyroidectomy
and duration of survival in our group of patients. Larger
proportion of patients without a total or completion thy-
roidectomy had more advanced disease, so they were
treated with EBRT, chemotherapy and radioiodine more
frequently than patients after a total thyroidectomy.
Interestingly, estimated median disease-specific survival
from the initial treatment in patients with and without
total thyroidectomy was 145 months in both groups of
patients. Furthermore, there was no statistically signifi-
cant difference in median disease-specific survival of
both groups of patients from the time of diagnosis of
distant metastases. This suggests possible impact of more
aggressive combined treatment on survival of patients.
Pittas et al. reported that nine patients with bone metas-
tases of HCTC have longer survival in comparison to 74
patients with bone metastases of follicular, papillary, or
undifferentiated thyroid carcinoma [31]. Our results con-
firm their observation that patients with metastatic HCTC
have a long survival. Median disease-specific survival from
the diagnosis of metastatic disease for our 8 patients with
bone metastases was 148 months. Five-year and ten-year
disease-specific survival was 70 % and 50 %, respectively.
It is interesting that our four patients with multiple
organ metastases had 100 % 5-year survival from the
first treatment and 75 % from the time of diagnosis
of distant dissemination. It should be stressed that,
the number of patients with multiple organ metasta-
ses in our series is very small. Survival of larger series
of patients with multiple metastases should be ana-
lyzed in order to find out if these patients have more
favorable prognosis in comparison to solitary organ
metastases. Most likely these four patients had more
slowly progressing tumor in comparison to other 28
patients. The other possible explanation is that their
tumor was very responsive to treatment: all four had
RAI ablation of thyroid remnant, three had therapy
with chemotherapy and RAI and all four had EBRT.Longer survival of patients with HCTC in comparison
to other types of differentiated thyroid carcinoma is
probably due to more indolent course of HCTC [31].
However, also HCTC is a progressive disease, so treat-
ment of recurrent and/or metastatic HCTC is necessary
in all those patients who are not extremely old or with
severe concomitant diseases.
Conclusions
Ten-year disease-specific survival for patients with meta-
static HCTC was 60 %. Patients with bone metastases
live longer than patients with lung metastases.
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